Circulating free DNA: a new surrogate marker for minimal residual disease?
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Tanja Fehm Malgorzata Banys
- چاپ و سال / کشور: 2011
Description
Despite progress made in the oncologic therapy, the prognosis of the patients with breast cancer is still limited by metastatic relapse often many years after primary diagnosis. Of all validated prognostic factors, monitoring of minimal residual disease (MRD) is the only one available after the primary tumor has been removed. Beside detection of circulating or disseminated tumor cells (DTC), there is currently a major effort to identify other biological markers which can be assessed with minimally invasive methods and persist beyond surgery.
Breast Cancer Res Treat DOI 10.1007/s10549-011-1392-7 Received: 24 January 2011 / Accepted: 2 February 2011
